Key result
CYP3A4*22 genotype effects on bleeding risk in ticagrelor users were analyzed using UK Biobank data, but the abstract provides only a data availability statement without clinical results.
Why the study?
Does CYP3A4*22 affect bleeding risk in ticagrelor users?
Does CYP3A4*22 affect bleeding risk in ticagrelor users?
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Asiimwe et al. (2024) studied this question. CYP3A4*22 genotype effects on bleeding risk in ticagrelor users were analyzed using UK Biobank data, but the abstract provides only a data availability statement without clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: